2024
Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation
Reddy K, Paltiel A, Freedberg K, Rigotti N. Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation. JAMA Health Forum 2024, 5: e242647. PMID: 39177985, PMCID: PMC11344233, DOI: 10.1001/jamahealthforum.2024.2647.Peer-Reviewed Original ResearchConceptsPublic health benefitsCessation medicationsSmoking cessationStop smokingLife yearsLong-term abstinenceCivilian noninstitutionalized adultsTobacco cessation treatmentTobacco cessation medicationsPotential public health benefitsPopulation-level life expectancyLife expectancySmoking cessation medicationsLife expectancy gainsHealth benefitsPotential public health impactPublic health impactSmoking cessation aidTobacco cessationNoninstitutionalized adultsNoninstitutionalized populationMain OutcomesCessation treatmentCessation aidsYear of availabilityTobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study
Thielking A, Fitzmaurice K, Sewpaul R, Chrysanthopoulou S, Dike L, Levy D, Rigotti N, Siedner M, Wood R, Paltiel A, Freedberg K, Hyle E, Reddy K. Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study. Journal Of The International AIDS Society 2024, 27: e26315. PMID: 38924347, PMCID: PMC11197963, DOI: 10.1002/jia2.26315.Peer-Reviewed Original ResearchMeSH KeywordsAdultComputer SimulationFemaleHIV InfectionsHumansLife ExpectancyMaleMiddle AgedSmoking CessationSouth AfricaTobacco SmokingConceptsMortality hazard ratioSmoking cessationLife yearsNever smoking statusLife expectancyVirologically suppressed PWHSmoking statusTobacco smokeIntegrate tobacco cessation interventionsMortality riskHazard ratioTobacco cessation interventionsSmoking cessation increasesTobacco-related illnessesImpact of tobacco smokingAntiretroviral therapyMortality risk increaseProportion of deathsChronic respiratory conditionsImpact of smokingCohort of PWHVirological non-suppressionCessation interventionsVirologic suppressionHIV care
2019
Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis. PLOS ONE 2019, 14: e0219068. PMID: 31247009, PMCID: PMC6597104, DOI: 10.1371/journal.pone.0219068.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioImmediate ARTImmediate ART initiationART initiationBudget impactLife expectancyImmediate antiretroviral therapy initiationDecrease HIV transmissionLate ART initiationModest budget impactAntiretroviral therapy initiationMedical resource useCost-effectiveness ratioCost-effectiveness analysisTherapy initiationHIV infectionHIV transmissionCôte d'IvoireART costsART efficacySTART trialCare budgetCD4CareOutcomes
2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal Of Infectious Diseases 2017, 216: 798-807. PMID: 29029344, PMCID: PMC5853503, DOI: 10.1093/infdis/jix349.Peer-Reviewed Original ResearchConceptsNational HIV/AIDS StrategyIncremental cost-effectiveness ratioHuman immunodeficiency virusCost-effectiveness ratioUS National HIV/AIDS StrategyHIV/AIDS StrategyAntiretroviral therapy costsSubstantial clinical benefitHigh HIV prevalenceGeneral US populationYears of lifeVirologic suppressionViral suppressionClinical outcomesAdherence interventionsClinical benefitHIV prevalenceHIV transmissionImmunodeficiency virusMSM populationAIDS StrategyTherapy costsTreatment targetsUS populationBlack men
2016
Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study
Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, Walensky RP. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. The Journal Of Infectious Diseases 2016, 214: 1672-1681. PMID: 27815384, PMCID: PMC5144729, DOI: 10.1093/infdis/jiw430.Peer-Reviewed Original ResearchConceptsSmoking statusSmoking cessationUS smokersLife expectancyT-cell countsHIV treatment programsAge 40 yearsYears of lifeSex-specific dataAntiretroviral therapyInitial CD4Current smokersFormer smokersHIV diseaseHIV infectionCigarette smokingMortality riskSmokersHIVSmoke cigarettesYounger ageTreatment programCessation ageSmokingCessationSurvival benefits of antiretroviral therapy in Brazil: a model‐based analysis
Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, MacLean RL, Parker RA, Paltiel AD, Walensky RP. Survival benefits of antiretroviral therapy in Brazil: a model‐based analysis. Journal Of The International AIDS Society 2016, 19: 20623. PMID: 27029828, PMCID: PMC4814587, DOI: 10.7448/ias.19.1.20623.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsBrazilCD4 Lymphocyte CountHIV InfectionsHumansLife ExpectancyModels, TheoreticalConceptsAntiretroviral therapyHIV-positive patientsSurvival benefitART initiationEligible HIV-positive patientsProvision of ARTDramatic survival benefitsSubsequent ART regimensMean CD4 countLife expectancyNumber of patientsProjected life expectancyART regimensCD4 countHigher CD4HIV diseaseRegimen efficacyLife expectancy increasesEra 1PatientsTherapyNational programExpectancyCD4Regimens
2014
HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?
Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, Paltiel AD, Kelly KA, Seage GR, Walensky RP, Weinstein MC, Eron J, Freedberg KA. HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? PLOS ONE 2014, 9: e113031. PMID: 25397616, PMCID: PMC4232561, DOI: 10.1371/journal.pone.0113031.Peer-Reviewed Original Research
2012
Newer drugs and earlier treatment
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment. AIDS 2012, 26: 45-56. PMID: 22008655, PMCID: PMC3237010, DOI: 10.1097/qad.0b013e32834dce6e.Peer-Reviewed Original ResearchConceptsCD4 cell countAntiretroviral therapyHIV RNACD4 cellsHIV diseaseCells/Life expectancyCell countMean CD4 cell countMean age 38 yearsAge 38 yearsMedical resource utilizationLifetime costsUndiscounted life expectancyCost of careAIDS Complications (CEPAC) modelART initiationHIV CostRegimen costsAntiretroviral drugsART costsEarly treatmentCopies/High-income countriesEfficacious drugs
2011
Medical Device Innovation — Is “Better” Good Enough?
Suter LG, Paltiel AD, Rome BN, Solomon DH, Golovaty I, Gerlovin H, Katz JN, Losina E. Medical Device Innovation — Is “Better” Good Enough? New England Journal Of Medicine 2011, 365: 1464-1466. PMID: 22010911, PMCID: PMC3570242, DOI: 10.1056/nejmp1109285.Peer-Reviewed Original ResearchThe Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: 26-35. PMID: 21068674, PMCID: PMC3005842, DOI: 10.1097/qai.0b013e3181fb8f24.Peer-Reviewed Original ResearchConceptsVoluntary HIV screeningQuality-adjusted life yearsHIV screeningLife yearsHIV case detectionHIV testing costsTest acceptance rateIncremental cost-effectiveness ratioSubstantial clinical benefitIncidence/prevalenceOne-time screeningDirect medical costsLife expectancyQuality-adjusted life expectancyCost-effectiveness ratioAntiretroviral therapyAnnual incidenceClinical benefitHIV prevalenceClinical impactCase detectionMedical costsCare ratesHIVTest acceptance
2010
Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA, Investigators F. Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. Clinical Infectious Diseases 2010, 51: 392-400. PMID: 20617921, PMCID: PMC2906630, DOI: 10.1086/655130.Peer-Reviewed Original ResearchConceptsHIV RNA levelsAntiretroviral therapyLife expectancyAdministration of ARTHuman immunodeficiency virus (HIV) epidemicART initiation strategiesHIV case detectionRNA levelsUndiagnosed HIV prevalenceCells/microLEarly case identificationInitial mean ageRegular screening programsHIV screeningHIV testAnnual incidenceAnnual screeningHIV prevalenceHIV transmissionHIV strategiesMean ageHIV epidemicCase detectionScreening programART efficacy
2009
Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. Clinical Infectious Diseases 2009, 49: 1570-1578. PMID: 19845472, PMCID: PMC2783631, DOI: 10.1086/644772.Peer-Reviewed Original ResearchConceptsEarly discontinuationHIV infectionAntiretroviral therapyYears of lifeLate initiationRisk behaviorsLate presentationHuman immunodeficiency virus (HIV) infectionHIV Research NetworkLate treatment initiationCohort of HIVImmunodeficiency virus infectionLife expectancyStandardized mortality ratioGeneral US populationHigh-risk profileYears of ageHigh-risk behaviorsSimilar demographic characteristicsRace/ethnicityART discontinuationART initiationCare concordantHispanic HIVAdvanced diseaseCost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA, AIDS F, investigators A. Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLOS Medicine 2009, 6: e1000173. PMID: 19859538, PMCID: PMC2762030, DOI: 10.1371/journal.pmed.1000173.Peer-Reviewed Original ResearchConceptsHIV treatment programsResource-limited settingsPerson/yearART initiationAIDS Complications-International modelTreatment programWorld Health Organization criteriaAntiretroviral therapy initiationLTFU ratesHIV careTherapy initiationCumulative incidenceClinical benefitOrganization criteriaClinical impactLTFUPayer perspectiveCost of interventionInternational criteriaLife expectancyEfficacyInterventionPreventing LossCareSurvival lossWhen to start antiretroviral therapy in resource-limited settings.
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Annals Of Internal Medicine 2009, 151: 157-66. PMID: 19620143, PMCID: PMC3092478, DOI: 10.7326/0003-4819-151-3-200908040-00138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAnti-Infective AgentsCD4 Lymphocyte CountCohort StudiesComputer SimulationCost-Benefit AnalysisDecision TreesDisease ProgressionDrug Administration ScheduleHealth Care CostsHIV InfectionsHumansLife ExpectancySensitivity and SpecificitySouth AfricaTrimethoprim, Sulfamethoxazole Drug CombinationConceptsAntiretroviral therapyCD4 countLong-term survivalCells/LART initiationCells/L.ART initiation strategiesIncremental cost-effectiveness ratioSevere opportunistic diseaseDoris Duke Charitable FoundationLife expectancyCD4 count thresholdHIV treatment decisionsCost-effectiveness ratioInternational clinical trialsBase-case analysisResource-limited settingsYears of lifeCost-effectiveness analysisPerson's life expectancyObservational cohortCD4 thresholdHIV diseaseTreatment guidelinesEarly therapy
2006
The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening.
Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Annals Of Internal Medicine 2006, 145: 646-53. PMID: 17088577, DOI: 10.7326/0003-4819-145-9-200611070-00006.Peer-Reviewed Original ResearchConceptsChronic illnessColorectal cancerChronic conditionsLife expectancyCancer stageEarly-stage colorectal cancerPopulation-based cancer registriesPatients 67 yearsRetrospective cohort studyStage I cancerAdministrative claims dataChronic condition groupsFinal study sampleYears of ageShort life expectancyCohort studyEffect of agePatient ageI cancerCancer RegistryCancer variesHealthy patientsIndividual patientsMedicare claimsAdministrative claims
2004
A therapeutic HIV vaccine: how good is good enough?
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? Vaccine 2004, 22: 4044-4053. PMID: 15364455, DOI: 10.1016/j.vaccine.2004.03.059.Peer-Reviewed Original Research
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trials
2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfectionState AIDS Drug Assistance Programs
Johri M, Paltiel A, Goldie S, Freedberg K. State AIDS Drug Assistance Programs. Medical Care 2002, 40: 429-441. PMID: 11961477, DOI: 10.1097/00005650-200205000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsCD4 Lymphocyte CountCost of IllnessCost-Benefit AnalysisDirect Service CostsDisease ProgressionEfficiency, OrganizationalEligibility DeterminationHealth Services AccessibilityHumansInsurance CoverageInsurance, Pharmaceutical ServicesLife ExpectancyMedical AssistanceModels, EconometricOrganizational InnovationQuality-Adjusted Life YearsState Health PlansUnited StatesConceptsQuality-adjusted life yearsLifetime direct medical costsLife yearsDirect medical costsDrug Assistance ProgramsAssistance programsState-transition simulation modelQuality-adjusted life expectancyADAP programEconomic performanceLife expectancyMedical costsCost-effective useLifetime costsCost dataServices Utilization SurveyState policyAIDS CostState AIDSCoverage variesComprehensive policyUtilization SurveyPolicyCare resourcesPessimistic assumptionsProphylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. JAMA Internal Medicine 2002, 162: 921-928. PMID: 11966344, DOI: 10.1001/archinte.162.8.921.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-Infective AgentsAntiprotozoal AgentsAtovaquoneCD4 Lymphocyte CountCost-Benefit AnalysisDapsoneDrug CostsHumansLife ExpectancyModels, TheoreticalNaphthoquinonesPentamidinePneumonia, PneumocystisPractice Guidelines as TopicQuality-Adjusted Life YearsConceptsQuality-adjusted life yearsCD4 cell countQuality-adjusted life expectancyPneumocystis carinii pneumoniaCD4 cell count increasePCP prophylaxisCell count increaseCell countCarinii pneumoniaClinical guidelinesCD4 cell count criteriaInitial CD4 cell countCD4 lymphocyte countPrimary PCP prophylaxisActive antiretroviral therapyCohort of HIVHuman immunodeficiency virusTMP/SMXCount increaseAntiretroviral therapyLymphocyte countHIV infectionImmunodeficiency virusTrimethoprim-sulfamethoxazoleProphylaxis